Influence of FK 506 (Tacrolimus) On Circulating CD4 ⁺ T Cells Expressing Cd25 and Cd45ra Antigens in 19 Patients with Chronic Progressive Multiple Sclerosis Participating in an Open Label Drug Safety Trial

References

• Kino T., Hatanaka H., Miyata S., Inamura N., Nishiyama M., Yajima T., Goto T., Okuhara M., Kohsaka M., Aoki H., Ochiai T. FK 506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK 506 in vitro. J. Antibiot. 1987; 40: 1256–1265
   PubMed Web of Science ®Google Scholar
• Zeevi A., Duquesnoy R., Eiras G., Rabinowich H., Todo S., Makowka L., Starzl T E. Immunosuppressive effect of FK 506 on in vitro lymphocyte alloactivation: synergism with cyclosprin A. Transplant Proc. 1987; 19: 40–44
   PubMed Web of Science ®Google Scholar
• Thomson A W. FK 506 –How much potential?. Immunol. Today 1989; 10: 6–9
   PubMedGoogle Scholar
• Thomson A W., Woo J., Fung J J., Starzl T E. FK 506: pharmacology and molecular action. Cell Directed Immunointervention, J-F Bach. Blackwell Scientific Publications, Oxford 1993; 121–137
   Google Scholar
• Tocci M J., Matkovich D A., Collier K A., Kwok P., Dumont F., Lin S., Degudicibus S., Siekierka J J., Chin J., Hutchinson N I. The immunosuppressant FK 506 selectively inhibits expression of early T cell activation genes. J. Immunol. 1989; 143: 718–726
   PubMed Web of Science ®Google Scholar
• Woo J., Sewell H F., Thomson A W. The influence of FK 506 and low concentration cyclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis. Scand. J. Immunol. 1990; 31: 297–304
   PubMedGoogle Scholar
• Woo J., Ross C S.K., Milton J I., Thomson A W. Immunosuppressive activity of FK 506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal. Clin. Exp. Immunol. 1990; 79: 109–114
   PubMed Web of Science ®Google Scholar
• Starzl T E., Fung J J., Venkataramanan R., Todo S., Deme-Tris A J., Jain A. FK 506 for liver, kidney and pancreas transplantation. Lancet 1989; ii: 1000–1004
   Google Scholar
• Abu-Elmagd K., van Thiel D., Jegasothy B V., Ackerman CD., Todo S., Fung J J., Thomson A W., Starzl T E. FK 506: a new therapeutic agent for severe rccalcitrantpsoriasis. Transplant Proc. 1991; 23: 3322–3324
   PubMed Web of Science ®Google Scholar
• Japanese FK. 506 Study Group on Refractory Uveitis A multicenter clinical open trial of FK 506 in refractory uveitis, including Behcet's disease. Transplant Proc. 1991; 23: 3343–3346
   PubMedGoogle Scholar
• Thomson A W., Nalesnik M., Rilo H., Woo J., Carroll P B., van Thiel D H. ICAM-1 and E-selectin expression in lesional biopsies of psoriasis patients responding to systemic FK 506 therapy. Autoimmunity 1993; 15: 215–223
   PubMed Web of Science ®Google Scholar
• McCauley J., Shapiro R., Ellis D., Igdal H., Tzakis A., Starzl T E. A pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome. Nephrol. Dial Transplant 1993; 8: 1286–1290
   PubMed Web of Science ®Google Scholar
• Thomson A W., Carroll P B., McCauley J., Wo J., Starzl T E., Abu-Elmagd K., van Thiel D H.Fk. 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh. Semin. Immunopathol. 1993; 14: 323–344
   Google Scholar
• Hafler D A., Weincr H L.MS. a CNS and systemic autoimmune disease. Immunol. Today 1989; 10: 104–107
   PubMedGoogle Scholar
• Hintzen R Q., Polamn C H., Lucas C J., van Lier R A.W. Multiple sclerosis: immunological findings and possible implications for therapy. J. Neuroimmunol 1992; 39: 1–10
   PubMedGoogle Scholar
• Martin R, McFarland H F., McFarlin D E. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 1992; 10: 153–87
   PubMed Web of Science ®Google Scholar
• Sanders M E., Makgoba M W., Shaw S. Human naive and memory T cells: reinterpretation of helper-inducer and suppressor-inducer subsets. Immunol. Today 1988; 9: 195–199
   PubMedGoogle Scholar
• Rose L M., Ginsburg A H., Rothstein T L., Ledbetter J A., Clark E A. Selective loss of a subset of T helper cells in active multiple sclerosis. Proc. Natl Acad. Sci. USA 1985; 82: 7389–7393
   PubMed Web of Science ®Google Scholar
• Emry P., Gentry K C., Mackay I R., Muirden K D., Rowley M. Deficiency of the suppressor-inducer subset of T lymphocytes in rheumatoid arthritis. Arthritis Rheum. 1987; 30: 849–853
   PubMedGoogle Scholar
• Lebranchu Y., Thibault G., Degene D., Bardos P. Deficiency of CD4+ CD45R+ T lymphocytes in common variable immunodeficiency. N. Engl. J. Med. 1990; 323: 276–277
   PubMedGoogle Scholar
• Mortimoto C, Hafler D A., Weiner H L., Letvin N L., Hagan M., Daley J., Schlossman S F. Selective loss of suppressor-inducer T-cell subset in progressive multiple sclerosis. N. Engl. J. Med. 1987; 316: 67–72
   PubMedGoogle Scholar
• Kurtzke J F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452
   PubMed Web of Science ®Google Scholar
• Hauser S L., Dawson D M., Lehrich J R. Intensive immunosuppression in progressive multiple sclerosis. N. Engl. J. Med. 1983; 308: 173–180
   PubMed Web of Science ®Google Scholar
• The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Annals, of Neurology 1990; 27: 591–605
   PubMed Web of Science ®Google Scholar
• McMichael J., Lieberman R., Doyle H., McCauley J., Fung J., Starzl T E. An intelligent and cost-effective computer dosing system for individualizing FK 506 therapy in transplantation and autoimmune disorders. J. Clin. Pharmacol. 1993; 33: 599–605
   PubMedGoogle Scholar
• Tamura K., Kobayashi M., Hashimoto K., Kojima K., Nagase K. A highly sensitive method to assay FK 506 levels in plasma. Transplant Proc. 1987; 19: 23–29
   PubMed Web of Science ®Google Scholar
• Collett D. Moedelling Binary Data. Chapman, Hall, London 1991
   Google Scholar
• Fung J J., Alessiani M., Abu-Elmagd K., Todo S., Shapiron R., Tzakis A., van Thiel D., Armitage J., Jain A., McCauley J., Selby R., Starzl T E. Adverse effects associated with the use of FK 506. Transplant Proc. 1991; 23: 3105–3108
   PubMed Web of Science ®Google Scholar
• Eidelman B H., Abu-Elmagd K., Wilson J. Neurologic complications of FK 506. Transplant. Proc. 1991; 23: 3175–3178
   PubMed Web of Science ®Google Scholar
• Ellison G W., Mickey M R., Myers L W. Alternative to randomized clinical trials. Neurology 1988; 38: 73–75
   PubMedGoogle Scholar
• Hafler D A., Fox D A., Manning S E., Schlossman S F., Reinherz E L., Weiner H L. In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N. Engl. J. Med. 1985; 312: 1405–1411
   PubMed Web of Science ®Google Scholar
• Hofman F M., von Hanwehr R I., Dinarello C A. Immuno-regultory molecules and IL-2 receptors identified in multiple sclerosis brain. J. Immunol. 1986; 136: 3239–3245
   PubMed Web of Science ®Google Scholar
• Thomson A V., Woo J., Lemster B., Irish W., Huang L L., Carroll P B., Rilo H R, Abu-Elmagd K. and Eidelman B. Incidence of CD4+ IL-2Ra+ andCD4+ CD45RA+ T-cells in progressive multiple sclerosis and the influence of short-term (three months) FK506 therapy. Ann. NY. Acad. Sci. 1993; 696: 245–251
   PubMed Web of Science ®Google Scholar
• Mochizuki M., Masuda K., Sakane T., Inaba G., Ito K., Kogure M. A multi-centre clinical open trial of FK 506 in refractory uveitis, including Behcet's disease. Transplant Proc. 1991; 23: 3343–3346
   PubMed Web of Science ®Google Scholar
• Lemster B., Rilo H R., Carroll P B., Nalesnik M A., Thomson A W. FK 506 inhibits cytokine gene and adhesion molecule expression in psoriatic skin lesions. Ann. NY. Acad. Sci. 1993; 696: 250–256
   PubMedGoogle Scholar
• Lemster B., Carroll P B., Rilo H R., Johnson N., Nikaein A., Thomson A W. IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus therapy. Clin. Exp. Immunol.
   Google Scholar